Lastly, durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) are used for non-small cell lung cancer and hepatocellular carcinoma, enhancing the immune response by targeting different checkpoints [42–44]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.